Article ID Journal Published Year Pages File Type
9383774 Archivos de Bronconeumología 2005 9 Pages PDF
Abstract
The mean cost was €1555.70. The costs of moderate and severe exacerbations were 4 and 12 times that of a mild exacerbation, respectively. Long-acting β2 agonists were less widely used than recommended by the guidelines for treatment of moderate and severe persistent asthma leading to asthma exacerbations.
Related Topics
Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine
Authors
, , , , , , ,